Patents by Inventor Amato Giaccia

Amato Giaccia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER
    Publication number: 20220409612
    Abstract: Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
    Type: Application
    Filed: February 15, 2022
    Publication date: December 29, 2022
    Inventors: Amato Giaccia, Jeanne Noe, Hanna Sanoff, Joel E. Tepper, Andrew Z. Wang
  • TREATMENT OF CANCER
    Publication number: 20210060003
    Abstract: Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
    Type: Application
    Filed: May 14, 2020
    Publication date: March 4, 2021
    Inventors: Amato Giaccia, Jeanne Noe, Hanna Sanoff, Joel E. Tepper, Andrew Z. Wang
  • TREATMENT OF CANCER
    Publication number: 20190070169
    Abstract: Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
    Type: Application
    Filed: August 31, 2018
    Publication date: March 7, 2019
    Inventors: Amato Giaccia, Jeanne Noe, Hanna Sanoff, Joel E. Tepper, Andrew Z. Wang
  • TREATMENT OF CANCER
    Publication number: 20170065723
    Abstract: In one aspect, the disclosure features, a method of treating a cancer, e.g. colorectal cancer, e.g., rectal cancer, in a subject with a cyclodextrin containing polymer (“CDP”)-camptothecin conjugate, particle or composition or camptothecin derivative conjugate, particle or composition described herein, e.g., CRLX101. The method comprises: providing an initial administration of a CDP-camptothecin conjugate, particle or composition or camptothecin derivative conjugate, particle or composition described herein, e.g., CRLX101.
    Type: Application
    Filed: September 26, 2014
    Publication date: March 9, 2017
    Inventors: Amato Giaccia, Jeanne Noe, Hanna Sanoff, Joel E. Tepper, Andrew Z. Wang
  • Substituted benzamides and their uses
    Patent number: 9296732
    Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 29, 2016
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Auckland UniServices, Limited, Ruga Corporation
    Inventors: Amato Giaccia, Edwin Lai, Olga Razorenova, Denise Chan, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Ray Tabibiazar, Po-wai Yuen
  • SUBSTITUTED BENZAMIDES AND THEIR USES
    Publication number: 20150329503
    Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
    Type: Application
    Filed: July 20, 2015
    Publication date: November 19, 2015
    Inventors: Amato Giaccia, Edwin Lai, Olga Razorenova, Denise Chan, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Ray Tabibiazar, Po-wai Yuen
  • Substituted benzamides and their uses
    Patent number: 9085570
    Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: July 21, 2015
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Auckland UniServices Limited, Ruga Corporation
    Inventors: Amato Giaccia, Edwin Lai, Olga Razorenova, Denise Chan, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Ray Tabibiazar, Po-wai Yuen
  • Synthetic lethal targeting of glucose transport
    Patent number: 9079859
    Abstract: The present invention provides methods for inhibiting growth and proliferation of HIF pathway proficient cells by administering GLUT1 inhibitors of the invention to HIF pathway proficient cells.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: July 14, 2015
    Assignees: AUCKLAND UNISERVICES LIMITED, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, RUGA CORPORATION
    Inventors: John Irwin, Patrick Sutphin, Denise Chan, Sandra Turcotte, Amato Giaccia, Edwin Lai, Olga Razorenova, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Raymond Tabibiazar
  • SUBSTITUTED BENZAMIDES AND THEIR USES
    Publication number: 20150072976
    Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 12, 2015
    Inventors: Amato Giaccia, Edwin Lai, Olga Razorenova, Denise Chan, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Ray Tabibiazar, Po-wai Yuen
  • USE OF PROLYL HYDROXYLASE INHIBITORS AS A RADIOPROTECTIVE DRUG FOR THE LOWER GASTROINTESTINAL TRACT
    Publication number: 20140315999
    Abstract: The present invention provides compositions and methods for treating or protecting mucosal tissues from damage associated with radiation and/or chemotherapy. Specifically, the instant invention is directed to inhibitors of prolyl hydroxylase domain (PHD) proteins and the use of such inhibitors in treating or protecting the gastrointestinal tract from damage associated with radiation.
    Type: Application
    Filed: August 24, 2012
    Publication date: October 23, 2014
    Inventors: Amato Giaccia, Cullen Taniguchi
  • SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT
    Publication number: 20140128397
    Abstract: The present invention provides methods for inhibiting growth and proliferation of HIF pathway proficient cells by administering GLUT1 inhibitors of the invention to HIF pathway proficient cells.
    Type: Application
    Filed: January 20, 2012
    Publication date: May 8, 2014
    Inventors: John Irwin, Patrick Sutphin, Denise Chan, Sandra Turcotte, Amato Giaccia, Edwin Lai, Olga Razorenova, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Raymond Tabibiazar
  • Substituted Benzamides and Their Uses
    Publication number: 20140024649
    Abstract: Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
    Type: Application
    Filed: October 10, 2011
    Publication date: January 23, 2014
    Applicants: Auckland UniServices Limited, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato Giaccia, Edwin Lai, Olga Razorenova, Denise Chan, Michael Patrick Hay, Muriel Bonnet, Connie Sun, Ray Tabibiazar, Po-wai Yuen
  • Method and composition for treating and preventing tumor metastasis in vivo
    Publication number: 20070225242
    Abstract: Methods, compositions and kits are provided for effectively treating and preventing cancer metastasis in vivo and for increasing survival of subjects burdened with metastatic tumors by targeting a lysyl oxidase or its modulator, especially human lysyl oxidase. Also provided are methods for identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.
    Type: Application
    Filed: January 25, 2007
    Publication date: September 27, 2007
    Inventors: Janine Erler, Amato Giaccia
  • Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
    Publication number: 20070021365
    Abstract: Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.
    Type: Application
    Filed: June 20, 2006
    Publication date: January 25, 2007
    Inventors: Janine Erler, Amato Giaccia
  • Methods and compositions for regulating adipogenesis
    Publication number: 20050282167
    Abstract: According to the disclosure hypoxia-mediated adipogenic inhibition involves the repression of PPAR?2 expression and its activity is a common mechanism for adipogenic inhibition by a variety of stimuli. The present disclosure relates to methods and compositions for regulating adipogenesis. The disclosure provides compositions comprising one or more DEC1/Stra13 fragments of capable of inhibiting PPAR?2 promoter activity. These fragments, e.g. the basic helix loop helix domain or amino acids 1-141, have substantially the same PPAR?2 promoter repressing activity as the full length polypeptide. The present disclosure provides methods of inhibiting adipogenesis comprising contacting a cell with a fragment of DEC1/Stra13. The invention further relates to methods and compositions of inhibiting angiogenesis in a tumor comprising contacting a tumor or tumor cell with a DEC1/Stra13 agonist.
    Type: Application
    Filed: February 28, 2003
    Publication date: December 22, 2005
    Inventors: Amato Giaccia, Zhong Yun
  • Anaerobe targeted enzyme mediated prodrug therapy
    Patent number: 6652849
    Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: November 25, 2003
    Assignees: The Board of Trustees of the Leland Standford Junior University, Microbiological Research Authority through the Centre for Applied Microbiology Research
    Inventors: John Martin Brown, Nigel P. Minton, Amato Giaccia
  • Anaerobe targeted enzyme mediated prodrug therapy
    Publication number: 20020182229
    Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.
    Type: Application
    Filed: May 17, 2002
    Publication date: December 5, 2002
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John Martin Brown, Nigel P. Minton, Amato Giaccia
  • Anaerobe targeted enzyme-mediated prodrug therapy
    Patent number: 6416754
    Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.
    Type: Grant
    Filed: July 23, 1996
    Date of Patent: July 9, 2002
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Microbiological Research Authority (MRA) acting through the Centre for Applied Microbiology and Research (CAMR)
    Inventors: John Martin Brown, Nigel P. Minton, Amato Giaccia